Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

MET in human cancer: germline and somatic mutations.

Tovar EA, Graveel CR.

Ann Transl Med. 2017 May;5(10):205. doi: 10.21037/atm.2017.03.64. Review.

2.

HGF-Met Pathway in Regeneration and Drug Discovery.

Matsumoto K, Funakoshi H, Takahashi H, Sakai K.

Biomedicines. 2014 Oct 31;2(4):275-300. doi: 10.3390/biomedicines2040275. Review.

3.

Molecular mechanisms of activating c-MET in KSHV+ primary effusion lymphoma.

Lam BQ, Dai L, Li L, Qiao J, Lin Z, Qin Z.

Oncotarget. 2017 Mar 14;8(11):18373-18380. doi: 10.18632/oncotarget.15444.

4.

Implementing Genome-Driven Oncology.

Hyman DM, Taylor BS, Baselga J.

Cell. 2017 Feb 9;168(4):584-599. doi: 10.1016/j.cell.2016.12.015. Review.

PMID:
28187282
5.

MET: roles in epithelial-mesenchymal transition and cancer stemness.

Jeon HM, Lee J.

Ann Transl Med. 2017 Jan;5(1):5. doi: 10.21037/atm.2016.12.67. Review.

6.

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Pilotto S, Gkountakos A, Carbognin L, Scarpa A, Tortora G, Bria E.

Ann Transl Med. 2017 Jan;5(1):2. doi: 10.21037/atm.2016.12.33. Review.

7.

Hepatocyte growth factor/MET in cancer progression and biomarker discovery.

Matsumoto K, Umitsu M, De Silva DM, Roy A, Bottaro DP.

Cancer Sci. 2017 Mar;108(3):296-307. doi: 10.1111/cas.13156. Review.

8.

MET receptor variant R970C favors calpain-dependent generation of a fragment promoting epithelial cell scattering.

Montagne R, Baranzelli A, Muharram G, Catherine L, Lesaffre M, Vinchent A, Kherrouche Z, Werkmeister E, Cortot AB, Tulasne D.

Oncotarget. 2017 Feb 14;8(7):11268-11283. doi: 10.18632/oncotarget.14499.

9.

The Role of BCA2 in the Endocytic Trafficking of EGFR and Significance as a Prognostic Biomarker in Cancer.

Wymant JM, Hiscox S, Westwell AD, Urbé S, Clague MJ, Jones AT.

J Cancer. 2016 Dec 9;7(15):2388-2407. eCollection 2016.

10.

MET expression and copy number status in clear-cell renal cell carcinoma: prognostic value and potential predictive marker.

Macher-Goeppinger S, Keith M, Endris V, Penzel R, Tagscherer KE, Pahernik S, Hohenfellner M, Gardner H, Grüllich C, Schirmacher P, Roth W.

Oncotarget. 2017 Jan 3;8(1):1046-1057. doi: 10.18632/oncotarget.13540.

11.

MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life.

Drilon A.

Clin Cancer Res. 2016 Jun 15;22(12):2832-4. doi: 10.1158/1078-0432.CCR-16-0229. Epub 2016 Mar 23.

12.

Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.

Gray MJ, Kannu P, Sharma S, Neyt C, Zhang D, Paria N, Daniel PB, Whetstone H, Sprenger HG, Hammerschmidt P, Weng A, Dupuis L, Jobling R, Mendoza-Londono R, Dray M, Su P, Wilson MJ, Kapur RP, McCarthy EF, Alman BA, Howard A, Somers GR, Marshall CR, Manners S, Flanagan AM, Rathjen KE, Karol LA, Crawford H, Markie DM, Rios JJ, Wise CA, Robertson SP.

Am J Hum Genet. 2015 Dec 3;97(6):837-47. doi: 10.1016/j.ajhg.2015.11.001.

13.

c-Met as a Target for Personalized Therapy.

Garajová I, Giovannetti E, Biasco G, Peters GJ.

Transl Oncogenomics. 2015 Nov 23;7(Suppl 1):13-31. doi: 10.4137/TOG.S30534. eCollection 2015. Review.

14.

Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma.

Dai L, Trillo-Tinoco J, Cao Y, Bonstaff K, Doyle L, Del Valle L, Whitby D, Parsons C, Reiss K, Zabaleta J, Qin Z.

Blood. 2015 Dec 24;126(26):2821-31. doi: 10.1182/blood-2015-07-658823. Epub 2015 Nov 3.

15.

Dysregulation of the Met pathway in non-small cell lung cancer: implications for drug targeting and resistance.

Sacco JJ, Clague MJ.

Transl Lung Cancer Res. 2015 Jun;4(3):242-52. doi: 10.3978/j.issn.2218-6751.2015.03.05. Review.

16.

Activating MET kinase rearrangements in melanoma and Spitz tumours.

Yeh I, Botton T, Talevich E, Shain AH, Sparatta AJ, de la Fouchardiere A, Mully TW, North JP, Garrido MC, Gagnon A, Vemula SS, McCalmont TH, LeBoit PE, Bastian BC.

Nat Commun. 2015 May 27;6:7174. doi: 10.1038/ncomms8174.

17.

Role of mesenchymal-epithelial transition amplification in resistance to anti-epidermal growth factor receptor agents.

Califano R, Morgillo F, De Mello RA, Mountzios G.

Ann Transl Med. 2015 Apr;3(6):81. doi: 10.3978/j.issn.2305-5839.2015.03.44. Review.

18.

Induction of c-Cbl contributes to anti-cancer effects of HDAC inhibitor in lung cancer.

Wei TT, Lin YC, Lin PH, Shih JY, Chou CW, Huang WJ, Yang YC, Hsiao PW, Chen CC.

Oncotarget. 2015 May 20;6(14):12481-92.

19.

Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein.

Navis AC, van Lith SA, van Duijnhoven SM, de Pooter M, Yetkin-Arik B, Wesseling P, Hendriks WJ, Venselaar H, Timmer M, van Cleef P, van Bergen En Henegouwen P, Best MG, Wurdinger TD, Tops BB, Leenders WP.

Acta Neuropathol. 2015 Jul;130(1):131-44. doi: 10.1007/s00401-015-1420-5. Epub 2015 Apr 11.

20.

cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance.

Van Der Steen N, Pauwels P, Gil-Bazo I, Castañon E, Raez L, Cappuzzo F, Rolfo C.

Cancers (Basel). 2015 Mar 25;7(2):556-73. doi: 10.3390/cancers7020556. Review.

Supplemental Content

Support Center